Mahnu Davar and Philip Desjardins Join FDA Watch Podcast To Discuss AI’s Expanding Role in Drug and Device Commercialization
Life Sciences & Healthcare Regulatory partners Mahnu Davar and Philip Desjardins were featured in FDA Watch’s podcast series, “AI, Medical Products & FDA: AI in Drug & Device Commercialization,” alongside Dr. William Maisel of Intuitive Surgical. The conversation marked the final installment in the series produced in collaboration with Arnold & Porter and explored the evolving use of artificial intelligence in healthcare regulation and commercialization.
Davar, who co-chairs the firm’s Life Sciences and Healthcare Regulatory practice, and Desjardins, who brings nearly two decades of experience with the FDA’s Center for Devices and Radiological Health, offered insights on the use of AI in clinical decision support, regulatory and pharmacovigilance functions, diagnostic and monitoring tools, and the impact of AI on advertising and promotion. The episode also addressed the concept of “AI washing” — the mislabeling of technologies as AI — and discussed the significance of the FDA’s first AI-assisted scientific review pilot.
